文献速递MDS 与骨髓增殖性肿瘤

基于血常规的可临床应用模型:辅助鉴别纤维化前原发性骨髓纤维化与原发性血小板增多症

A Clinically Applicable Model Using Blood Counts to Support the Diagnosis of Prefibrotic Myelofibrosis Versus Essential Thrombocythemia.
PubMed 文献 · Am J Hematol · 2025-07-26

研究利用891例原发性血小板增多症(ET)和180例纤维化前原发性骨髓纤维化(pre-PMF)患者数据,基于白细胞(WBC)与血小板(PLT)水平交互的logistic回归模型预测pre-PMF概率。以WBC 8.85×10^9/L和PLT 793×10^9/L为阈值分组,双低组pre-PMF预测概率最低(6%),双高组最高(26%),后者为前者的四倍以上;校正乳酸脱氢酶(LDH)和脾肿大后关联仍显著(p<0.001)。提示WBC与PLT同时升高可作为辅助鉴别ET与pre-PMF的实用诊断工具,并可在早期孤立性血小板增多症中推迟骨髓活检。

要点

  • WBC与PLT双低组pre-PMF预测概率为6%,更符合ET特征。
  • WBC或PLT任一升高时pre-PMF概率约18%-19%,双高组达26%。
  • 双高组pre-PMF概率为双低组四倍以上,校正LDH和脾肿大后仍显著(p<0.001)。

核心结论

  • WBC与PLT同时升高可作为辅助鉴别ET与pre-PMF的实用诊断工具,并可在早期孤立性血小板增多症不确定时推迟骨髓活检。

研究设计与样本

  • 基于891例ET和180例pre-PMF患者数据的logistic回归模型研究,以WBC 8.85×10^9/L和PLT 793×10^9/L为阈值将患者分为四组。

主要发现

  • WBC与PLT双低组pre-PMF预测概率最低(6%),提示更符合ET特征。
  • WBC或PLT任一升高时pre-PMF概率约18%-19%,提示可能向pre-PMF特征偏移。
  • WBC与PLT双高组pre-PMF预测概率最高(26%),为双低组的四倍以上。
  • 校正血清LDH和脾肿大后,WBC/PLT联合水平与pre-PMF诊断的关联仍显著(p<0.001)。

关键数值与推荐

  • WBC阈值8.85×10^9/L,PLT阈值793×10^9/L。
  • 双低组pre-PMF预测概率6%,单高组约18%-19%,双高组26%。
  • 校正LDH和脾肿大后关联显著性p<0.001。

临床怎么用

  • 作者认为WBC与PLT同时升高可作为辅助鉴别ET与pre-PMF的实用、可及诊断工具,并可在早期孤立性血小板增多症不确定时推迟骨髓活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to distinguish between essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF) using routine blood tests, with a focus on white blood cell (WBC) and platelet (PLT) levels. We evaluated the predicted probability of a pre-PMF diagnosis based on the interaction between WBC and PLT levels using data from a logistic regression model involving 891 patients with ET and 180 patients with pre-PMF. Patients were divided into four groups based on whether their WBC and PLT values were below or above the respective thresholds of 8.85 × 109/L and 793 × 109/L. The results showed that patients with low levels of both WBCs and PLTs had the lowest predicted probability of pre-PMF (6%), indicating a profile more typical of ET. When either WBC or PLT levels were elevated, the probability increased to approximately 18%-19%, indicating a potential shift toward pre-PMF features. Notably, patients with elevated levels of both WBCs and PLTs had the highest probability of a pre-PMF diagnosis (26%), which was more than four times higher than that of the low-low group. The association between combined WBC/PLT levels and a pre-PMF diagnosis remained significant (p < 0.001), even when adjusting for serum lactate dehydrogenase (LDH) and splenomegaly. These findings suggest that elevated WBC and PLT levels together can serve as a practical and accessible diagnostic tool for supporting the differential diagnosis of ET or pre-PMF in cases of uncertainty, and for deferring bone marrow biopsy in cases of early disease presenting with isolated thrombocytosis.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Barbui T, Thiele J, Ghirardi A, et al. A Clinically Applicable Model Using Blood Counts to Support the Diagnosis of Prefibrotic Myelofibrosis Versus Essential Thrombocythemia. Am J Hematol. 2025. PMID: 40716107. doi:10.1002/ajh.70017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。